Summit Therapeutics Files US Annual Report on Form 20F

Summit Therapeutics plc
("Summit", or the "Company")

Summit Therapeutics Files US Annual Report on Form 20-F

Oxford, UK, and Cambridge, MA, US, 13 April 2018 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT) provides notification that the Company has today filed its US Annual Report on Form 20-F for the year ended 31 January 2018 with the US Securities and Exchange Commission ("SEC").

The Form 20-F is available to download, either from the Investors section of the Company website at www.summitplc.com or from the SEC website at www.sec.gov.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

-END-